Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
One of the most common mechanisms of immune evasion in MSI colorectal cancers (CRCs) is loss of HLA class I expression due to mutations in B2M gene which can become a negative predictor for checkpoint blockade therapy. The aim of this study was the determination of prevalence of B2M somatic mutations in MSI CRC patients and relationship between B2M mutations and lymphocytes infiltration and other clinicopathological features as well as detection of methylation changes in B2M promoter region which can be another mechanism of immune escape. In our study, 37 MSI-H and 5 MSI-L patients were selected for screening of B2M mutational and methylation status. The characterization of patients was based on standard histopathological diagnosis and TNM classification; BRAF, KRAS mutations, tumor-infiltrating lymphocytes and peritumoral lymphoid reaction were also determined. MSI analysis was performed using fragment analysis. B2M mutations were identified by Sanger sequencing, and methylation of CpG islands in promoter region was detected by methylation-specific PCR. Heterozygous mutations in the B2M gene were detected in five MSI-H patients (13.5%), while the mutation c.45_48delTTCT was determined in four patients and mutation c.276delC was found in two patients. One of these five patients was compound heterozygote harboring both mutations. Methylation of the promoter region of the B2M gene was observed in one patient with MSI-H colorectal cancer. Detection of genetic and epigenetic changes in B2M gene could be important in personalized therapy for CRC patients as these changes may be one of the mechanisms of secondary resistance of MSI positive tumors to immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetic and epigenetic aberrations leading to defects in antigen presentation can promote primary and acquired resistance to ICB regardless of TMB (Snahnicanova et al., 2020; Sucker et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Snahnicanova et al., 2020
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“High mutational load leading to increased neoepitopes presentation and high immunogenicity of MSI cancers make them suitable candidates for immunotherapy by immune checkpoint inhibitors which block immune checkpoint molecules like PD-1 (programmed cell death protein 1) or CTLA4 (cytotoxic T lymphocyte-associated prote…”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“This hypothesis is supported by the increased accumulation of B2M mutations during and after therapy by immune checkpoint inhibitors [7, 8, 20, 21, 44].”
BackgroundType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“These strategies include positive selection of antigens lacking cancer cells and defects in antigen presentation through defects in expression of HLA molecules or in antigen processing pathways [33, 34].”
BackgroundMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 3×
“In our study, we focused on the detection of mutational and methylation status of B2M gene as mechanisms leading to downregulation or loss of gene expression and consequently to impaired antigen presentation, immune evasion and immunotherapy resistance [21].”
BackgroundMethodClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · cited 1×
“High mutational load leading to increased neoepitopes presentation and high immunogenicity of MSI cancers make them suitable candidates for immunotherapy by immune checkpoint inhibitors which block immune checkpoint molecules like PD-1 (programmed cell death protein 1) or CTLA4 (cytotoxic T lymphocyte-associated prote…”
BackgroundMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 1×
“From the clinical point of view, colorectal cancer patients with high level of MSI have favorable prognosis and lower frequency of distant metastases compared to microsatellite stable (MSS) tumors [1, 3, 4].”
BackgroundPagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60702-2 · Cited by 1,928
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078 · cited 1×
“These strategies include positive selection of antigens lacking cancer cells and defects in antigen presentation through defects in expression of HLA molecules or in antigen processing pathways [33, 34].”
BackgroundResistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005 · cited 2×
“This hypothesis is supported by the increased accumulation of B2M mutations during and after therapy by immune checkpoint inhibitors [7, 8, 20, 21, 44].”
BackgroundAberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
Baylin, S. B. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.687 · Cited by 929
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787 · cited 2×
“This hypothesis is supported by the increased accumulation of B2M mutations during and after therapy by immune checkpoint inhibitors [7, 8, 20, 21, 44].”
BackgroundGenetic Mechanisms of Immune Evasion in Colorectal Cancer
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1327 · Cited by 535
Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
Santini, V., Kantarjian, H. M., & Issa, J.-P. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00011 · Cited by 414
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
Campoli, M., & Ferrone, S. (2008) · Oncogene · doi:10.1038/onc.2008.273 · Cited by 404
The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes
Kim, T.-M., Laird, P. W., & Park, P. J. (2013) · Cell · doi:10.1016/j.cell.2013.10.015 · Cited by 380
Jenkins, M. A., Hayashi, S., O’Shea, A.-M., Burgart, L. J., Smyrk, T. C., Shimizu, D., Waring, P. M., Ruszkiewicz, A. R., Pollett, A. F., Redston, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.044 · Cited by 373
NLRC5/MHC class I transactivator is a target for immune evasion in cancer
Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B., Sidiq, T., Shipp, M. A., Lizee, G. A., & Kobayashi, K. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602069113 · Cited by 276
Buckowitz, A., Knaebel, H.-P., Benner, A., Bläker, H., Gebert, J., Kienle, P., von Knebel Doeberitz, M., & Kloor, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602534 · Cited by 264
The Immune Biology of Microsatellite-Unstable Cancer
Kloor, M., & von Knebel Doeberitz, M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.02.004 · Cited by 245
Serrano, A., Tanzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239
Nie, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1615 · Cited by 202
Transcriptional regulation of antigen presentation
van den Elsen, P. J., Holling, T. M., Kuipers, H. F., & van der Stoep, N. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.11.015 · Cited by 172
Genetic evolution of T-cell resistance in the course of melanoma progression
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0567 · Cited by 171 · cited 1×
“This hypothesis is supported by the increased accumulation of B2M mutations during and after therapy by immune checkpoint inhibitors [7, 8, 20, 21, 44].”
BackgroundCabrera, C. M., Jiménez, P., Cabrera, T., Esparza, C., Ruiz‐Cabello, F., & Garrido, F. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00020.x · Cited by 164
Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.
Bicknell, D. C., Rowan, A., & Bodmer, W. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4751 · Cited by 150
Immune evasion of microsatellite unstable colorectal cancers
Kloor, M., Michel, S., & von Knebel Doeberitz, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25283 · Cited by 138
Selection for β2-microglobulin mutation in mismatch repair-defective colorectal carcinomas
Bicknell, D., Kaklamanis, L., Hampson, R., Bodmer, W. F., & Karran, P. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70795-1 · Cited by 132
Immune selective pressure and HLA class I antigen defects in malignant lesions
Chang, C., & Ferrone, S. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0183-1 · Cited by 129
Beta2‐microglobulin mutations in microsatellite unstable colorectal tumors
Kloor, M., Michel, S., Buckowitz, B., Rüschoff, J., Büttner, R., Holinski‐Feder, E., Dippold, W., Wagner, R., Tariverdian, M., Benner, A., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22691 · Cited by 114
Chang, C.-C., Campoli, M., Restifo, N. P., Wang, X., & Ferrone, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1462 · Cited by 95
Tikidzhieva, A., Benner, A., Michel, S., Formentini, A., Link, K. H., Dippold, W. G., Doeberitz, M. V. K., Kornmann, M., & Kloor, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.53 · Cited by 76
Ye, Q., Shen, Y., Wang, X., Yang, J., Miao, F., Shen, C., & Zhang, J. (2010) · Tissue Antigens · doi:10.1111/j.1399-0039.2009.01390.x · Cited by 65
Janikovits, J., Müller, M., Krzykalla, J., Körner, S., Echterdiek, F., Lahrmann, B., Grabe, N., Schneider, M. A., Benner, A., Doeberitz, M. V. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1390640 · Cited by 65
Ding, S. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i23.3433 · Cited by 62
A Histology-Based Model for Predicting Microsatellite Instability in Colorectal Cancers
Hyde, A. J., Fontaine, D., Stuckless, S. N., Green, R., Pollett, A. F., Simms, M., Sipahimalani, P., Parfrey, P. S., & Younghusband, B. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181f6a912 · Cited by 51
Koelzer, V. H., Baker, K., Kassahn, D., Baumhoer, D., & Zlobec, I. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-200742 · Cited by 43
Harlé, A., Busser, B., Rouyer, M., Harter, V., Génin, P., Leroux, A., & Merlin, J. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1380-x · Cited by 39
Yeon, S. Y., Jung, S., Jo, Y. S., Choi, E. J., Kim, M. S., Chung, Y., & Lee, S. H. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.11.014 · Cited by 39
Qifeng, S., Bo, C., Xingtao, J., Chuanliang, P., & Zhao, X. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.04.031 · Cited by 35
Clinico-pathologic Parameters for Prediction of Microsatellite Instability in Colorectal Cancer
Jung, S., Lee, H.-I., Oh, H. K., Shin, I.-H., & Jeon, C. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.179 · Cited by 32
Hill, D. M., Kasliwal, T., Schwarz, E., Hebert, A. M., Chen, T., Gubina, E., Zhang, L., & Kozlowski, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208381200 · Cited by 31
Yamamoto, H., Yamashita, K., & Perucho, M. (2001) · Gastroenterology · doi:10.1053/gast.2001.24497 · Cited by 28
Lasabová, Z., Tilandyova, P., Kajo, K., Žúbor, P., Burjanivová, T., Danko, J., & Plank, L. (2010) · Neoplasma · doi:10.4149/neo_2010_01_035 · Cited by 27
Self-citationJašek, K., Buzalková, V., Minárik, G., Štanclová, A., Szepe, P., Plank, L., & Lasabová, Z. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2044-4 · Cited by 27
Self-citationOn behalf of investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort, Clendenning, M., Huang, A., Jayasekara, H., Lorans, M., Preston, S., O’Callaghan, N., Pope, B. J., Macrae, F. A., Winship, I. M., et al. (2018) · Familial Cancer · doi:10.1007/s10689-017-0013-y · Cited by 25
Váňová, B., Kalman, M., Jašek, K., Kašubová, I., Burjanivová, T., Farkašová, A., Kružliak, P., Büsselberg, D., Plank, L., & Lasabová, Z. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00545-y · Cited by 25
Self-citationLasabová, Z., Kalman, M., Holubeková, V., Grendár, M., Kašubová, I., Jašek, K., Meršaková, S., Malicherová, B., Baranenko, D., Adamek, M., et al. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00558-7 · Cited by 11
Self-citationStratification of patients with colorectal cancer without the recorded family history
Kašubová, I., Kalman, M., Jašek, K., Burjanivov�, T., Malicherov�, B., Vaňochov�, A., Meršaková, S., Lasabov�, Z., & Plank, L. (2019) · Oncology Letters · doi:10.3892/ol.2019.10018 · Cited by 10
Self-citationGyőrffy, B., Nagy, Á. M., Pongor, L. S., Locatelli, A., Viganò, L., Safonov, A. M., Pusztai, L., Gianni, L., & Bianchini, G. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.11547 · Cited by 3
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“In patients with MSI colorectal cancer, promoter methylation at the B2M gene was observed [54].”
BackgroundResistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
Wang, H., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.008 · Cited by 190
Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
Mulet-Margalef, N., Linares, J., Badia-Ramentol, J., Jimeno, M., Sanz, C., Mozo, J. L. M., & Calon, A. (2023) · Cancers · doi:10.3390/cancers15041022 · Cited by 124
Metadata
- Authors
- Snahnicanova, Z., Kasubova, I., Kalman, M., Grendar, M., Mikolajcik, P., Gabonova, E., Laca, L., Caprnda, M., Rodrigo, L., Ciccocioppo, R., Kruzliak, P., Plank, L., & Lasabova, Z.
- Affiliations
- Martin University Hospital (SK)
- Comenius University Bratislava (SK)
- University of Verona (IT)
- Venue
- Clinical and Experimental Medicine
- Published
- 2019-12-18
- Volume
- 20
- Issue
- 1
- Pages
- 87-95
- ISSN
- 1591-8890 (ISSN-L)
- 1591-9528
- OpenAlex
- W2995284100
- Cited by
- 29
- References
- 55
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 5 · 2020: 3
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical and Experimental Medicine (publishedVersion)
- PubMed (publishedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Funders
- Agentúra Ministerstva Školstva, Vedy, Výskumu a Športu SR (APVV-16-0066)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- beta2-microglobulin, microsatellite instability, colorectal cancer, immune evasion, HLA class I loss, promoter methylation, tumor-infiltrating lymphocytes, immunotherapy resistance, checkpoint blockade, compound heterozygosity
- MeSH terms
- Adult, Aged, Aged, 80 and over, beta 2-Microglobulin, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Promoter Regions, Genetic, Colorectal Neoplasms, Down-Regulation, Gene Expression Regulation, Neoplastic, CpG Islands, DNA Methylation, Epigenesis, Genetic, Microsatellite Instability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.